Respiratory Syncytial Virus Vaccine for Children

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness in infants and young children. Prevention strategies have expanded beyond supportive care to include maternal immunization and long-acting monoclonal antibody protection for eligible infants. Policy decisions increasingly depend on evidence about disease burden, seasonality, safety, delivery capacity, access, and coordination between maternal and pediatric services.

The pediatric RSV landscape is shifting toward layered prevention. Public-health programs are combining maternal vaccination during pregnancy with infant immunoprophylaxis, while countries refine eligibility rules to avoid unnecessary duplication. Implementation is also moving toward more deliberate seasonal planning, including supply coordination, clinical guidance, cold-chain readiness, risk communication, and monitoring of uptake and adverse events.

Artificial intelligence can support RSV prevention by improving seasonal surveillance, identifying geographic and demographic patterns, optimizing inventory allocation, and helping health systems prioritize outreach. It may also assist with clinical decision support and signal detection in safety monitoring. These applications require representative data, transparent validation, privacy safeguards, human oversight, and careful separation between decision support and clinical judgment.

North America has established pediatric and maternal immunization infrastructure but must address seasonal supply, eligibility coordination, and equitable access. Europe is navigating differences in national recommendations, procurement, and reimbursement across health systems. Asia-Pacific combines advanced programs with major gaps in access and surveillance, making adaptable delivery models important. Latin America is strengthening routine immunization and maternal-care integration while managing uneven coverage. The Middle East requires coordination across public, private, migrant, and humanitarian health services. Africa faces substantial surveillance and delivery constraints, with prevention strategies needing to align with broader maternal and child-health platforms and local epidemiology.

ASEAN members face diverse health-system capacity, tropical and temperate transmission patterns, and varying access to maternal and infant services. BRICS countries must address wide internal disparities in surveillance, procurement, and delivery while strengthening domestic evidence. The European Union benefits from regulatory coordination but retains national differences in implementation and reimbursement. G7 members generally have stronger evidence and delivery infrastructure, yet equity and uptake remain priorities. GCC countries can leverage concentrated health systems and cross-border coordination, while NATO countries may benefit from interoperable preparedness, logistics, and emergency-planning capabilities without treating defense structures as substitutes for civilian health programs.

Australia should align seasonal guidance with state-based delivery and remote-community access. Brazil and Mexico need stronger integration between maternal care, pediatric services, and public immunization networks. Canada and the United States must manage jurisdictional variation, seasonal supply, and equitable access across vulnerable communities. China and India require scalable surveillance and delivery approaches suited to major regional differences. Japan and South Korea can build on advanced pediatric systems while maintaining clear eligibility and safety communication. France, Germany, Italy, Spain, and the United Kingdom face the operational task of translating national recommendations into consistent, accessible programs. Russia requires attention to surveillance quality, regional access, and transparent evidence communication.

Leaders should establish clear eligibility pathways that coordinate maternal vaccination and infant antibody protection, supported by consistent clinical communication. They should link procurement and inventory planning to local RSV seasonality, strengthen sentinel surveillance, and measure uptake by geography and social group. Programs should use trusted maternity, pediatric, primary-care, and community channels; prepare contingency plans for supply disruption; and publish understandable safety information. Evaluation should track hospitalization, missed opportunities, adverse events, access gaps, and real-world effectiveness while protecting personal data.

This executive summary is based on a structured review of authoritative public-health guidance, regulatory communications, peer-reviewed clinical and epidemiological literature, surveillance reporting, and documented implementation experience. Evidence was interpreted by comparing prevention options, eligibility frameworks, delivery settings, safety monitoring, health-system readiness, and regional variation. Findings were synthesized qualitatively across the required regions, country groups, and countries. No market estimates, market sizing, market shares, forecasts, or company-specific claims were used.

Pediatric RSV prevention is becoming a coordinated public-health function rather than a single-product intervention. The strongest programs will connect maternal and infant services, adapt to local seasonality and epidemiology, monitor safety and effectiveness, and protect access for underserved families. Sustained progress depends on transparent evidence review, reliable delivery systems, responsible use of data and artificial intelligence, and collaboration across national and regional health authorities.